Samir Ounzain

Scientist/CEO @HAYA_lncRNA ( Interested in the dark side of your genome and the RNAs produced by it #lncRNA

[HAYA Therapeutics @HAYA_lncRNA]

🚀#HAYATherapeutics has been recognized by #IDEAPharma as a #DisruptivePioneer!

This is a validation of our core mission: to advance investigational, precision #RNAguidedTherapies with the potential to tackle the actual root drivers of common and #ChronicDiseases.

[HAYA Therapeutics @HAYA_lncRNA]

➡️https://t.co/jhOclG3Cwz

A huge thank you to our team and everyone who helped us reach this important #milestone!

[HAYA Therapeutics @HAYA_lncRNA]

#HAYA is officially a #Clinical-stage company!

The first cohort has been dosed in our #Phase1 clinical trial evaluating #HTX001, a first-in-class investigational therapy targeting the #lncRNA #WISPER for #nHCM. 🫀

[HAYA Therapeutics @HAYA_lncRNA]

Attending #cshlregRNA next week? 🇺🇸

#HAYA’s Senior Director of Biology and Functional Genomics, Rudi Micheletti, will present our lead program, with an emphasis on the #MoA and precision #ASO targeting of #WISPER, the master lncRNA driving #MyocardialFibrosis.

Let’s connect! 🤝

[HAYA Therapeutics @HAYA_lncRNA]

By targeting this #lncRNA, we are reprogramming the #TME and offering a novel strategy to overcome treatment resistance in solid cancers.

Let’s connect in San Diego and discuss how we can drive this wave of #precision #innovation #together!🤝

[HAYA Therapeutics @HAYA_lncRNA]

Big news! #HAYA’s CEO @ispiyou has been named one of the @Citeline's #InVivo #RisingLeaders2026🏆

Congratulations, Samir! Your bold thinking and commitment to translating #CausalBiology into real-world impact drive the culture of #innovation at HAYA.

➡️ https://t.co/qbnojDICdh

[HAYA Therapeutics @HAYA_lncRNA]

HTX-001 is designed to address #CardiacFibrosis by #reprogramming cardiac myofibroblasts back to a healthy state, offering a potential #NovelTherapeuticOption for patients living with #HCM. 🫀

See you in Toronto!

[HAYA Therapeutics @HAYA_lncRNA]

✈️ Heading to the #PharmaPartneringSummitUS?

Connect with #HAYA CBO @drrichjlaw to explore our unique platform and next-gen #RNATherapies pipeline in: 🫀 Cardiovascular 🫁 Pulmonary 🔬 Oncology

Let's shape a new frontier in medicine #together. 🤝

[HAYA Therapeutics @HAYA_lncRNA]

Join us at the panel discussions!

➡️ Learn more at: https://t.co/BfQvVJTp20

See you in Basel!

[HAYA Therapeutics @HAYA_lncRNA]

#HAYA is heading to #SwissBiotechDay! 🇨🇭

Connect with our CEO @ispiyou and COO Eric Adam to learn more about HAYA’s unique approach and how targeting the #RegulatoryGenome holds the potential to deliver a more #precise, #durable, and #biologicallyGrounded #therapeutic strategy.

[Samir Ounzain @ispiyou]

@alexisohanian @shae_mcl check out @HAYA_lncRNA

[Rich Law @drrichjlaw]

Brilliant podcast with Samir Ounzain as he shares his journey & what led to the founding of HAYA Therapeutics; a biotech trailblazing an entirely new approach to treating common & chronic diseases by cell reprogramming via the regulatory genome. 🧬❤️🫁https://t.co/Bn1mgdnDNU

[Rich Law @drrichjlaw]

Super excited that we get to take this next step in the future of Haya Therapeutics! 🧬 🚀

[HAYA Therapeutics @HAYA_lncRNA]

🚀 We're thrilled to announce that #HAYATherapeutics have successfully raised $65Million in #SeriesA round of financing 🎉

A huge #THANKYOU to our TEAM, PARTNERS, and INVESTORS! 🙌
➡️https://t.co/lsRTHv8PbR

@SofinnovaVC @EarlybirdVC

[Rich Law @drrichjlaw]

I’m really thrilled to join up with Samir and the team at HAYA Therapeutics as their new Chief Business Officer!

[Samir Ounzain @ispiyou]

Thrilled to welcome Rich as our new Chief Business Officer! Rich has a stellar track record in biopharma partnerships, strategic growth, and innovation and his expertise at the intersection of biology and technology has helped reshape drug discovery!

[Rich Law @drrichjlaw]

I’m really thrilled to join up with Samir and the team at HAYA Therapeutics as their new Chief Business Officer!

[HAYA Therapeutics @HAYA_lncRNA]

📣 Today, we are thrilled to welcome @drrichjlaw
as #HAYATherapeutics’ #CBO!

Looking forward to the future ahead of us. Stay tuned for more exciting news!

https://t.co/vSUJIWIbCt

Welcome to the team Richard!🎉

[Labiotech.eu @Labiotech_eu]

This week, our podcast guest is Samir Ounzain, CEO of Haya Therapeutics. Ounzain was one of the first researchers to publish on lncRNA, also known as the ���dark genome.’ https://t.co/mLIJS6Hdaf

[Rory Johnson @_Rory_Johnson_]

👇🤯For everybody interested in #lncRNAs, the latest @GencodeGenes capture effort and resulting improved annotations are big news! Major increases in overall counts in human and mouse, better overlap with other collections and far higher human-mouse orthology rates